Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD)

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 300-304

  Miles, Michael V ^a,c   Tang, Peter H ^a   Ryan, Melody A ^b   Grim, Shellee A ^b   Fakhoury, Toufic A ^b   Strawsburg, Richard H ^a   DeGrauw, Ton J ^a   Baumann, Robert J ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Anticonvulsant; Antiepileptic drug; Epilepsy; Oxcarbazepine; Saliva; Therapeutic drug monitoring

Indexed keywords

LICARBAZEPINE; OXCARBAZEPINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; DRUG TRANSFORMATION; EPILEPSY; FEMALE; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; EPILEPSY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SALIVA;

EID: 2542633478     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00014     Document Type: Article

References (28)

1. Bartels H, Oldigs HD, Gunther E. Use of saliva in monitoring carbamazepine medication in epileptic children. Eur J Pediatr. 1977;126:37-44.
2. Miles MV, Tennison MB, Greenwood RS. Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 1990;12:501-510.
3. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet. 1992;23:365-379.
4. Grim SA, Ryan M, Miles MV, et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 2003;25:61-66.
5. Miles MV, Tang PH, Glauser TA, et al. Topiramate concentrations in saliva: an alternative to serum monitoring. Pediatr Neurol. 2003;29:143-147.
6. Ryan M, Grim SA, Miles MV, et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy. 2003;23:1550-1557.
7. Leppik IE. Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide. J Child Neurol. 2002;17(Suppl 1):S53-S57.
8. Tecoma ES. Oxcarbazepine. Epilepsia. 1999;40(Suppl 5):S37-S46.
9. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42:1023-1042.
10. Theisohn M, Heimann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol. 1982;22:545-551.
11. Kristensen O, Klitgaard NA, Jonsson B, et al. Pharmacokinetics of 10-OH carbamazepine the main metabolite of the antiepileptic oxcarbazepine from saliva and serum concentrations. Acta Neurol Scand. 1983;68:145-150.
12. Klitgaard NA, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol. 1986;31:91-94.
13. Cardot JM, Degen P, Flesch G, et al. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Biopharm Drug Distrib. 1995;16:603-614.
14. Ramachandran S, Underhill S, Jones SR. Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin, and carbamazepine using reversed-phase high-performance liquid chromatography at dual wavelengths. Ther Drug Monit. 1994;16:75-82.
15. ChromQuest® [computer program]. Version 2.51. Thermo Separation Products, San Jose, CA, USA; 1998.
16. Systat® [computer program]. Version 10.2. Chicago, IL, USA: SPSS Inc.; 2002.
17. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
18. Herkes GK, Eadie MJ. Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy. Epilepsy Res. 1990;6:146-154.
19. Rosenthal E, Hoffer E, Ben-Aryeh H, et al. Use of saliva in home monitoring of carbamazepine levels. Epilepsia. 1995;136:72-74.
20. Gorodischer R, Burtin P, Verjee Z, et al. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;6:437-443.
21. Bauchner H, Vinci R, Bak S, et al. Parents and procedures: a randomized controlled trial. Pediatrics. 1996;98:861-867.
22. Ritschel WA, Tompson GA. Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure. Methods Find Exp Clin Pharmacol. 1983;5:511-525.
23. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther. 1999;66:547-553.
24. Bialer M. Oxcarbazepine. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. New York: Lippincott Williams & Wilkins; 2002:459-465.
25. May TW, Rambeck B, Salke-Kellermann A. Fluctuations of 10-hydroxycarbazepine during the day in epileptic patients. Acta Neurol Scand. 1996;93:393-397.
26. Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol. 1990;39:413-415.
27. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord. 2002;72(Suppl 1):S23-S34.
28. Centorrino F, Albert MJ, Berry JM, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord. 2003;5:370-374.